Clinical trial

A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis

NCT00441103

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-12-01

PhasePHASE3

Study timeline

Study start (unknown)2006-12-01Date precision: month

Registry last updated2014-07-09

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosis, Relapsing-Remittingunresolved

Interventions

Rebif® New Formulation (IFN-beta-1a, RNF)DRUG

PlaceboDRUG

Rebif® New Formulation (IFN-beta-1a, RNF)DRUG

Sponsors & collaborators

Merck KGaA, Darmstadt, Germanylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00441103 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.